The venture is conducting research into an oral prolonged-release formulation of ketamine for treatment-resistant depression with minimal dissociative side effects.

The pharmacokinetic profile of the prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects compared to the currently applied intravenous and intranasal ketamine therapies resulting in a decreased need for monitoring under medical supervision.